Quarterly Financial Results
Jubilant Ingrevia Reports 25% Revenue Growth in Q1 FY27; EBITDA Rises 36% on Strong Specialty Chemicals and Nutrition Demand
NSE
jublingrea
BSE
543271
- Jubilant Ingrevia Limited reported a strong start to FY27, driven by healthy volume growth, improved product realizations and robust performance across its Specialty Chemicals, Nutrition & Health Solutions and Chemical Intermediates businesses.
- Total revenue increased 25% year-on-year to ₹1,300 crore, while EBITDA rose 36% to ₹209 crore.
- Profit after tax grew 41% to ₹106 crore, supported by stronger pricing, a favorable product mix and improved demand across pharmaceuticals, nutrition and agrochemicals.
- The company also highlighted growing momentum in its CDMO business and maintained confidence in sequential revenue and EBITDA improvement during FY27.
PRICE-SENSITIVE TRIGGER
Event: Jubilant Ingrevia Limited announced its financial results for the quarter ended June 30, 2026, along with an investor presentation outlining operational performance, business segment updates and the company’s growth outlook.
Type: Quarterly Financial Results
Impact: Positive
Immediate Effect: The company delivered double-digit growth across revenue, EBITDA and profit, supported by resilient demand in key end markets, improved pricing across multiple product categories and continued execution of its “Pinnacle” transformation strategy. Management also reiterated expectations for sequential improvement in revenue and profitability over the remaining quarters of FY27.
Metrics:
Key Financial Metrics:
- Revenue from Operations: ₹1,300 crore (▲25% YoY)
- Total EBITDA: ₹209 crore (▲36% YoY)
- EBITDA Margin: 16% (vs. 15% in Q1 FY26)
- Profit After Tax (PAT): ₹106 crore (▲41% YoY)
- PAT Margin: 8% (vs. 7% in Q1 FY26)
- Earnings Per Share (EPS): ₹6.7 (▲41% YoY)
- Profit Before Tax (PBT): ₹141 crore (▲41% YoY)
- Total Income: ₹1,310 crore (▲25% YoY)
Highlight:
- Jubilant Ingrevia delivered its highest quarterly revenue in the last fifteen quarters, supported by higher sales volumes, stronger realizations and improved profitability across all three business segments.
- EBITDA margin expanded to 16%, while PAT growth outpaced revenue growth due to operating leverage and favorable product mix.
What Happened ?
Jubilant Ingrevia began FY27 on a strong note, reporting its highest quarterly revenue in nearly four years as demand remained resilient across pharmaceuticals, nutrition, agrochemicals and specialty chemicals despite geopolitical uncertainties affecting global supply chains. Revenue from operations increased 25% year-on-year to ₹1,300 crore, while EBITDA rose 36% to ₹209 crore and profit after tax climbed 41% to ₹106 crore.
Performance was driven by healthy volume growth, improved product pricing and effective cost pass-through across businesses. Specialty Chemicals benefited from strong momentum in Fine Chemicals and CDMO operations, while Nutrition & Health Solutions recorded robust growth supported by higher Niacinamide and Choline realizations. The Chemical Intermediates segment delivered the sharpest improvement, aided by stronger demand, higher selling prices and improved margins.
During the quarter, the company also advanced its long-term “Pinnacle” strategy by expanding its CDMO pipeline, progressing construction of its Multi-Purpose Plant, integrating the Remidex Pharma acquisition and strengthening opportunities in semiconductor and electronics applications. Management expects Specialty Chemicals, Nutrition and a recovery in Acetyls to support continued sequential improvement in revenue and EBITDA during FY27.
key details
Specialty Chemicals Continued Steady Growth:
The Specialty Chemicals business remained the company’s largest contributor during Q1 FY27, supported by healthy demand across Fine Chemicals, CDMO and Pyridine derivatives. While volumes remained stable in Pyridine & Picolines, higher realizations, an improved product mix and increasing contribution from value-added offerings supported earnings growth.
Key Highlights:
- Segment revenue increased 11% YoY to ₹533 crore.
- EBITDA stood at ₹139 crore, up 7% YoY.
- EBITDA margin remained healthy at 26%.
- Fine Chemicals recorded healthy volume growth across Pyridine and Diketene derivatives, supported by improved pricing.
- Cosmetics pipeline expanded to 20+ products under development across sun care, skin care and hair care applications.
- Cost optimization initiatives helped offset pricing pressure in selected Pyridine products.
CDMO and Fine Chemicals Pipeline Expanded:
Jubilant Ingrevia continued strengthening its Custom Development and Manufacturing Organization (CDMO) business, supported by increasing customer engagement across pharmaceuticals, agrochemicals and semiconductor applications.
Key Highlights
- Agro CDMO business benefited from commercialization of innovator projects.
- Pharma pipeline expanded by more than 3x following customer roadshows in the US and Europe.
- Semiconductor business is establishing a dedicated R&D laboratory and clean-room facility in Greater Noida.
- The combined CDMO and Fine Chemicals pipeline exceeds 100 molecules, representing an estimated ₹3,500+ crore peak revenue opportunity.
- More than 25 molecules have already been confirmed for commercialization.
- Five new molecules were added during the quarter across pharma, semiconductor and personal care applications.
Nutrition & Health Solutions Delivered Strong Momentum:
The Nutrition & Health Solutions business recorded one of its strongest quarterly performances, driven by higher pricing across Niacinamide, Choline products and Premixes, along with healthy demand from domestic and export markets.
Key Highlights:
- Segment revenue increased 36% YoY to ₹243 crore.
- EBITDA rose 45% YoY to ₹36 crore.
- EBITDA margin improved to 15% from 14% a year earlier.
- Human Nutrition benefited from strong pricing in Niacinamide across food and cosmetics applications.
- Choline products recorded improved realizations across India, Europe and the United States.
- Premixes business strengthened relationships with Tier-1 customers following the successful integration of Remidex Pharma.
- Animal Nutrition delivered higher pricing while maintaining stable Vitamin B3 volumes and strong European demand for Choline products.
Chemical Intermediates Posted Strong Recovery:
The Chemical Intermediates segment reported the strongest year-on-year improvement among all business divisions, supported by higher product prices, improved demand and effective pass-through of elevated raw material costs.
Key Highlights:
- Segment revenue increased 38% YoY to ₹524 crore.
- EBITDA surged 240% YoY to ₹57 crore.
- EBITDA margin expanded sharply to 11%, compared with 4% in Q1 FY26.
- Acetic Anhydride maintained stable pharmaceutical demand while increasing market share in Europe.
- Ethyl Acetate recorded strong double-digit volume growth.
- Higher selling prices across the portfolio supported profitability amid elevated input costs linked to Middle East supply disruptions.
Pinnacle Strategy and Operational Excellence:
The company continued executing its long-term Pinnacle transformation strategy, focusing on operational efficiency, capacity expansion, ESG leadership and future growth platforms.
Key Highlights:
- Targeting ₹100 crore in lean operational savings during FY27.
- Multi-Purpose Plant remains on track for commissioning by the end of calendar year 2026.
- Successfully completed more than 20 customer quality and EHS audits during the quarter.
- Reported zero safety incidents across manufacturing facilities.
- Successfully integrated the Remidex Pharma acquisition, strengthening the nutrition business.
- Continued evaluating inorganic growth opportunities across electronics, semiconductors, cosmetics and nutrition.
- Hosted an Investor & Analyst Day at the Bharuch manufacturing facility to showcase operational capabilities and long-term growth initiatives.
Risk Analysis
Summary:
- Jubilant Ingrevia delivered a strong start to FY27 with broad-based growth across its three business segments, supported by healthy demand, improved pricing and higher operating efficiencies. While the company remains well positioned for continued growth through its Pinnacle strategy and expanding CDMO pipeline, future performance will depend on sustained customer demand, successful execution of expansion projects and stability in global chemical markets.
Key Risks:
- Geopolitical tensions and supply chain disruptions could lead to volatility in raw material availability and input costs.
- Demand recovery in the Chemical Intermediates business and Acetyls segment may be slower than anticipated.
- Delays in commissioning the Multi-Purpose Plant could postpone growth in CDMO and Fine Chemicals.
- Continued pricing pressure in certain specialty chemical products may affect margins despite cost optimization initiatives.
- Growth in the CDMO pipeline depends on successful commercialization of development-stage molecules and customer approvals.
- Export-oriented businesses remain exposed to changes in global demand, currency movements and international trade conditions.
Worst Case:
- If geopolitical disruptions intensify, customer demand weakens across key end markets and the company’s expansion projects face execution delays, revenue growth and profitability could moderate, while commercialization of the CDMO pipeline may take longer than expected.
Risk Level: Medium
Company Commentary
- Chairman Shyam S. Bhartia and Co-Chairman Hari S. Bhartia said the company delivered a strong start to FY27, with revenue increasing 25% YoY and EBITDA growing 36% YoY, reflecting disciplined execution and the strength of its diversified business portfolio.
- They noted resilient demand across pharmaceuticals, improving momentum in agrochemicals, healthy growth in nutrition and personal care, and increasing customer engagement in electronics and semiconductor applications.
- Management stated that the Pinnacle transformation strategy continues to strengthen the company’s growth trajectory through sustained volume growth, firmer pricing and an expanding opportunity pipeline.
- The company expects FY27 growth to be led by Specialty Chemicals and Nutrition & Health Solutions, alongside a recovery in Acetyls.
- Management also confirmed that the Multi-Purpose Plant remains on schedule for commissioning by the end of calendar year 2026, supporting future expansion in the CDMO and Fine Chemicals businesses.
Official Exchange Filing: Jubilant Ingrevia Limited
